PMID- 34733418
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211105
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 12
IP  - 22
DP  - 2021 Oct 26
TI  - Comparison of MET gene amplification analysis by next-generation sequencing and 
      fluorescence in situ hybridization.
PG  - 2273-2282
LID - 10.18632/oncotarget.28092 [doi]
AB  - MET gene alterations are known to be involved in acquired resistance to epidermal 
      growth factor receptor inhibition. MET amplifications present a potential 
      therapeutic target in non-small cell lung cancer. Although next-generation 
      sequencing (NGS) and fluorescence in situ hybridization (FISH) are conventionally 
      used to assess MET amplifications, there are currently no clinically defined 
      cut-off values for NGS, with FISH still being the gold standard. A collective of 
      20 formalin-fixed paraffin-embedded lung cancer tissue samples (mean age 64 
      years) were selected based on increased MET gene copy number (CNV) status or the 
      presence of mutations detected by NGS (GeneReader, QIAGEN) and were further 
      assessed by FISH (MET/CEN7, Zytomed). Of these, 17 tumor samples were 
      MET-amplified and one patient was found to have a MET rearrangement by NGS, while 
      two samples had no MET gene alteration. In contrast to the NGS result, FISH 
      analysis showed only one highly amplified sample and 19 negative samples. The 
      single highly amplified case detected by FISH was also positive by NGS with a 
      fold change (FC) of 3.18 and a mean copy number (CN(MV 10-100%)) of 20.5. 
      Therefore, for the assessment of MET amplifications using the QIAGEN NGS 
      workflow, we suggest detecting amplified cases with an FC value of >/= 3.0 and a 
      CN(MV 10-100%) value of >/= 20.0 by FISH. In summary, NGS allows for DNA- and 
      RNA-based analysis of specific MET gene amplifications, point mutations or 
      rearrangements.
CI  - Copyright: (c) 2021 Schmitt et al.
FAU - Schmitt, Christina
AU  - Schmitt C
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
FAU - Schulz, Anna-Alice
AU  - Schulz AA
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
FAU - Winkelmann, Ria
AU  - Winkelmann R
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
FAU - Smith, Kevin
AU  - Smith K
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
FAU - Wild, Peter J
AU  - Wild PJ
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
AD  - Wildlab, University Hospital Frankfurt MVZ GmbH, Frankfurt am Main 60590, 
      Germany.
AD  - Frankfurt Institute for Advanced Studies (FIAS), Frankfurt am Main 60438, 
      Germany.
FAU - Demes, Melanie
AU  - Demes M
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Frankfurt 
      am Main 60590, Germany.
AD  - Wildlab, University Hospital Frankfurt MVZ GmbH, Frankfurt am Main 60590, 
      Germany.
LA  - eng
PT  - Journal Article
DEP - 20211026
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC8555686
OTO - NOTNLM
OT  - MET amplification
OT  - fluorescence in situ hybridization (FISH)
OT  - next-generation sequencing (NGS)
OT  - non-small cell lung cancer (NSCLC)
OT  - routine diagnostics
COIS- CONFLICTS OF INTEREST Peter J. Wild: Advisory role and honoraria (institutional 
      or personal): AstraZeneca, Janssen, Roche, Astellas, Bayer, Bristol-Myers Squibb, 
      Janssen, Novartis, Thermo Fisher Scientific, MSD, QIAGEN, Molecular Health, 
      Sophia Genetics. Melanie Demes: Advisory role and honoraria (institutional or 
      personal): Amgen, AstraZeneca, Bayer, Diaceutics, Biocartis, Sophia Genetics.
EDAT- 2021/11/05 06:00
MHDA- 2021/11/05 06:01
PMCR- 2021/10/26
CRDT- 2021/11/04 06:24
PHST- 2021/06/11 00:00 [received]
PHST- 2021/09/28 00:00 [accepted]
PHST- 2021/11/04 06:24 [entrez]
PHST- 2021/11/05 06:00 [pubmed]
PHST- 2021/11/05 06:01 [medline]
PHST- 2021/10/26 00:00 [pmc-release]
AID - 28092 [pii]
AID - 10.18632/oncotarget.28092 [doi]
PST - epublish
SO  - Oncotarget. 2021 Oct 26;12(22):2273-2282. doi: 10.18632/oncotarget.28092. 
      eCollection 2021 Oct 26.